W. Gouraud

发表

Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response

Hamza Lasla, Wilfried Gouraud, Catherine Guérin-Charbonnel, 2015, Breast Cancer Research.

Logic programming reveals alteration of key transcription factors in multiple myeloma

N. Munshi, Carito Guziolowski, P. Moreau, 2017, Scientific Reports.

Gene-expression signature functional annotation of breast cancer tumours in function of age

M. Campone, L. Campion, P. Jézéquel, 2015, BMC Medical Genomics.

iTRAQ‐Based Quantitative Proteomic Analysis Strengthens Transcriptomic Subtyping of Triple‐Negative Breast Cancer Tumors

M. Campone, C. Guette, P. Jézéquel, 2019, Proteomics.

Early dynamic transcriptomic changes during preoperative radiotherapy in patients with rectal cancer: a feasibility study.

B. Buecher, M. Heymann, M. Mahé, 2013, World journal of gastroenterology.

A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Multiple Myeloma Patients

Ludovic, P. Sonneveld, A. Aussem, 2020 .

Validation of UBE2C protein as a prognostic marker in node-positive breast cancer

R. Bataille, M. Campone, G. Ricolleau, 2009, British Journal of Cancer.

Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome.

Laurence Lodé, Catherine Charbonnel, Wilfried Gouraud, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Minor clone provides a reservoir for relapse in multiple myeloma

N. Munshi, O. Decaux, P. Moreau, 2013, Leukemia.

Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen

Catherine Charbonnel, Wilfried Gouraud, Pascal Jézéquel, 2008, Breast Cancer Research and Treatment.

Inhibition of mTORC1 activity by REDD1 induction in myeloma cells resistant to bortezomib cytotoxicity

Catherine Charbonnel, Wilfried Gouraud, Stéphane Minvielle, 2010, Cancer science.

bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer

M. Campone, C. Leux, G. Ricolleau, 2012, Breast Cancer Research and Treatment.

Development of an absolute assignment predictor for triple-negative breast cancer subtyping using machine learning approaches.

Bertrand Michel, Mario Campone, Hamza Lasla, 2020, Computers in biology and medicine.

Prognostic significance of copy-number alterations in multiple myeloma.

Cheng Li, Kenneth C. Anderson, Catherine Charbonnel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications

J. Lemonnier, M. Campone, J. Canon, 2019, Breast Cancer Research.

A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma

P. Sonneveld, N. Munshi, A. Aussem, 2016, Clinical Cancer Research.

An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity: RUBY.

I. Bièche, F. André, C. Vicier, 2017 .

c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1

M. Campone, S. Barillé-Nion, P. Juin, 2011, Molecular Cancer.

Molecular characterization of the response to chemotherapy in conventional osteosarcomas: Predictive value of HSD17B10 and IFITM2

F. Chibon, S. Salas, D. Figarella-Branger, 2009, International journal of cancer.

Development of an absolute assignment predictor for triple-negative breast cancer subtyping using machine learning approaches

Bertrand Michel, Mario Campone, Fadoua Ben Azzouz, 2020, bioRxiv.